Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

Oncogene

Volumn 36, Issue 9, 2017, Pages 1223-1231

  Deng, X ^a   Shao, G ^a,b   Zhang, H T ^a,c   Li, C ^a,d   Zhang, D ^e   Cheng, L ^f   Elzey, B D ^g   Pili, R ^h   Ratliff, T L ^g,i   Huang, J ^j   Hu, C D ^a,i  

^a PURDUE UNIVERSITY   (United States)

^b JIANGSU UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d OHIO STATE UNIVERSITY   (United States)

^e PURDUE UNIVERSITY   (United States)

^f INDIANA UNIVERSITY   (United States)

^g PURDUE UNIVERSITY   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Purdue University   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HISTONE H2A; HISTONE H4; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 5; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; PRMT5 PROTEIN, HUMAN; SMARCA4 PROTEIN, HUMAN; SP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DU145 CELL LINE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PC 3 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TISSUE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RWPE 1 CELL LINE; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; DNA HELICASES; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN-ARGININE N-METHYLTRANSFERASES; RECEPTORS, ANDROGEN; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84983315937     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.287     Document Type: Article

References (53)

1. Bedford M, Clarke S. Protein arginine methylation in mammals: who, what, and why. Mol Cell 2009; 33: 1-13.
2. Krause CD, Yang ZH, Kim YS, Lee JH, Cook JR, Pestka S. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther 2007; 113: 50-87.
3. Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J et al. Arginine methylation controls growth regulation by E2F-1. EMBO J 2012; 31: 1785-1797.
4. Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J 2012; 446: 235-241.
5. Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyl-transferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res 2011; 71: 5579-5587.
6. Wang L, Pal S, Sif S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 2008; 28: 6262-6277.
7. Wei TY, Juan CC, Hsia JY, Su LJ, Lee YC, Chou HY et al. PRMT5 is a potential oncoprotein that upregulates G1 cyclins/CDKs and the PI3K/AKT signaling cascade. Cancer Sci 2012; 103: 1640-1650.
8. Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res 2014; 74: 1752-1765.
9. Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci 2011; 36: 633-641.
10. Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci 2015; 72: 2041-2059.
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
12. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-344.
13. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009; 5: 1403-1413.
14. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-3658.
15. Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med 2015; 13: 206.
16. Guo Z, Qiu Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?!. Int J Biol Sci 2011; 7: 815-822.
17. Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res 2014; 34: 6265-6269.
18. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormone Cancer 2014; 5: 265-273.
19. Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 2008; 617: 245-255.
20. Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Translat Androl Urol 2013; 2: 148-157.
21. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120: 719-733.
22. Gao L, Alumkal J. Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics 2010; 5: 100-104.
23. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60: 753-766.
24. Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005; 63: 117-130.
25. Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One 2012; 7: e44033.
26. Zhang HT, Zhang D, Zha ZG, Hu CD. Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta 2014; 1839: 1330-1340.
27. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
28. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papilloma-virus 18. Carcinogenesis 1997; 18: 1215-1223.
29. Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I et al. Androgen receptor drives cellular senescence. PLoS One 2012; 7: e31052.
30. Hsu CC, Hu CD. Transcriptional activity of c-Jun is critical for the suppression of AR function. Mol Cell Endocrinol 2013; 372: 12-22.
31. Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, Smith EM et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood 2015; 125: 2530-2543.
32. Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO, Trapman J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem 1993; 268: 9296-9301.
33. Tilley WD, Marcelli M, McPhaul MJ. Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J Biol Chem 1990; 265: 13776-13781.
34. Dacwag CS, Ohkawa Y, Pal S, Sif S, Imbalzano AN. The protein arginine methyl-transferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling. Mol Cell Biol 2007; 27: 384-394.
35. LeBlanc SE, Konda S, Wu Q, Hu YJ, Oslowski CM, Sif S et al. Protein arginine methyltransferase 5 (Prmt5) promotes gene expression of peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and its target genes during adipogenesis. Mol Endocrinol 2012; 26: 583-597.
36. Tee WW, Pardo M, Theunissen TW, Yu L, Choudhary JS, Hajkova P et al. Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev 2010; 24: 2772-2777.
37. Teng Y, Girvan AC, Casson LK, Pierce Jr WM, Qian M, Thomas SD et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 2007; 67: 10491-10500.
38. Hay CW, Hunter I, MacKenzie A, McEwan IJ. An Sp1 modulated regulatory region unique to higher primates regulates human androgen receptor promoter activity in prostate cancer cells. PLoS One 2015; 10: e0139990.
39. Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011; 21: 396-420.
40. Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M et al. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia 2015; 30: 789-799.
41. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J et al. mSin3A/ histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in tran-scriptional repression of the Myc target gene cad. Mol Cell Biol 2003; 23: 7475-7487.
42. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-asso-ciated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004; 24: 9630-9645.
43. Seth-Vollenweider T, Joshi S, Dhawan P, Sif S, Christakos S. Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3-induced 25-hydroxyvitamin D3 24-hydroxylase (Cyp24a1) Transcription: epigenetic modification involving crosstalk between protein-arginine methyltransferase 5 and the SWI/SNF complex. J Biol Chem 2014; 289: 33958-33970.
44. Liu C, Wang C, Wang K, Liu L, Shen Q, Yan K et al. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J Natl Cancer Institute 2013; 105: 1719-1728.
45. Hosohata K, Li P, Hosohata Y, Qin J, Roeder RG, Wang Z. Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription. Mol Cell Biol 2003; 23: 7019-7029.
46. Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol 2015; 11: 432-437.
47. Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM et al. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res 2011; 1: 834-844.
48. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 2009; 8: 498-504.
49. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X et al. One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 2004; 36: 826-828.
50. Nelson JD, Denisenko O, Sova P, Bomsztyk K. Fast chromatin immunoprecipitation assay. Nucleic Acids Res 2006; 34: e2.
51. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE et al. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated over-expression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res 2010; 70: 10182-10191.
52. Hedges LV, Olkin I. Statiscal Methods for Meta-Analysis. Academic Press: Orlando, FL, USA, 1985.
53. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychol Methods 1998; 3: 486-504.